Both liraglutide and semaglutide have received FDA approval for the treatment of T2DM, obesity, and cardiovascular risk reduction [ Table 2 ]
The STRIDE trial evaluated semaglutide in patients with T2DM and PAD, finding a 13% improvement in maximum walking distance and a significant increase in ankle-brachial index, indicating improved perfusion
(Salas-Whalen worked for Novo Nordisk in the past but on projects unrelated to Ozempic.) The recommended weight loss rate on Ozempic, Salas-Whalen notes, is 1 to 2 pounds per week
Its common to feel worried if youre not losing weight on tirzepatide
With proper nutrition and activity, men can preserve and support muscle mass while using GLP-1 therapy
Use of proportional reporting ratios (Prrs) for signal generation from spontaneous adverse drug reaction reports